Recently Published GRAS Notices and FDA Letters
For a full listing of notices and response letters, please visit the inventory database.
GRN No. | Substance | GRAS Notice | FDA Letter |
---|---|---|---|
1024 | D-psicose | GRN 1024 (in PDF 5.0MB) |
|
1017 | Lacto-N-tetraose | GRN 1017 (in PDF, 3.3 MB)” |
|
1016 | 6’-sialyllactose sodium salt | GRN 1016 (in PDF, 3.1 MB)” |
|
1015 | 3’-sialyllactose sodium salt | GRN 1015 (in PDF, 3.2 MB) |
|
1014 | 2'-fucosyllactose | GRN 1014 (in PDF 4.6 MB) |
|
1013 | Lactobacillus rhamnosus DSM 33156 | GRN 1013 (in PDF 18.0 MB) |
|
1012 | Powdered sap from Angelica keiskei (ashitaba) containing 8% chalcones (ashitaba sap) | GRN 1012 (in PDF, 5.1 MB) |
|
1011 | Alpha-amylase enzyme preparation produced by Bacillus subtilis strain AR-651 expressing the gene encoding alpha-amylase from Thermoactinomyces vulgaris | GRN 1011 (in PDF 2.0 MB) |
|
1009 | Water-soluble palm fruit extract | GRN 1009 (in PDF 1.0 MB) |
|
1008 | Algal oil (≥35% docosahexaenoic acid) from Aurantiochytrium limacinum TKD-1 | GRN 1008 (in PDF 2.7 MB) |
|
1007 | Bacillus-subtilis Strain R0179 | GRN 1007 Part 1 (in PDF 15.2 MB) GRN 1007 Part 2 (in PDF 12.82 MB) GRN 1007 Part 3 (in PDF 12.93 MB) GRN 1007 Part 4 (in PDF 11.84 MB) GRN 1007 Part 5 (in PDF 17.96 MB) GRN 1007 Part 6 (in PDF 11.01 MB) GRN 1007 Part 7 (in PDF 6.04 MB) |
|
1006 | Short-chain fructooligosaccharides | GRN 1006 (in PDF 516 KB) |
|
1003 | Bifidobacterium longum subsp. infantis M-63 | GRN 1003 (in PDF 1.6 MB) |
|
1002 | Bifidobacterium breve strain MCC1274 | GRN 1002 (in PDF 1.9 MB) |
|
1001 | Myoglobin preparation from a strain of Pichia pastoris expressing the myoglobin gene from Bos taurus | GRN 1001 with Amendment (in PDF 14.6 MB) |
FDA has no questions (in PDF 374 KB) |
1000 | Phycocyanin-rich extract of Galdieria sulphuraria (G. sulphuraria strain "FCC3424") | GRN 1000 (in PDF 2 MB) |
|
999 | Enzyme-modified steviol glycosides | GRN 999 (in PDF 5.2 MB) |
|
997 | Chitosan and beta-1, 3-glucans from white button mushrooms (Agaricus bisporus) | GRN 997 (in PDF 4.4 MB) |
|
996 | Synthetic amorphous silica | GRN 996 (in PDF 3.0 MB) |
|
995 | beta-glucans from Antrodia cinnamomea strain ATCC 200183 | GRN 995 (in PDF 3.2 MB) |
|
994 | Miracle fruit (Synsepalum dulcificum) in pulp, powder or protein forms | GRN 994 (in PDF 2.0 MB) |
FDA ceased to evaluate (in PDF 140 KB) |
993 | L-carnitine-L-tartrate | GRN 993 with Amendment (in PDF 3.0 MB) |
FDA has no questions (in PDF 149 KB) |
992 | White mulberry (Morus alba Linn) leaf extract | GRN 992 Part 1 (in PDF 19.0 MB) GRN 992 Part 2 (in PDF 8.9 MB) GRN 992 Part 3 (in PDF 17.7 MB) GRN 992 Part 4 (in PDF 14.3 MB) GRN 992 Part 5 (in PDF 11.8 MB) GRN 992 Part 6 (in PDF 13.0 MB) |
|
990 | Short-chain fructooligosaccharides | GRN 990 with Amendment (in PDF 9.0 MB) |
FDA has no questions (in PDF 118 KB) |
989 | Bacillus subtilis expressing a modified gene encoding a variant of the wild-type subtilisin from B. clausii | GRN 989 (in PDF 4.6 MB) |
|
988 | Lactobacillus fermentum LfQi6 | GRN 988 (in PDF 10.6 MB) |
|
987 | 2'-fucosyllactose | GRN 987 (in PDF 14.0 MB) |
|
986 | Chlorella sorokiniana powder and C. sorokiniana micro powder | GRN 986 (in PDF, 3.5 MB) |
FDA has no questions (in PDF 148 KB) |
985 | Bifidobacterium longum subsp. infantis strain ATCC SD 6720 | GRN 985 with Amendment (in PDF 11.6 MB) |
FDA has no questions (in PDF 338 KB) |
984 | Wolffia globosa | GRN 984 with Amendment (in PDF 5.4 MB) |
FDA ceased to evaluate (in PDF 142 KB) |
983 | Purified steviol glycosides from the leaves of Stevia rebaudiana (Bertoni) | GRN 983 (in PDF 4.4 MB) |
|
982 | Polygalacturonase enzyme preparation produced by Aspergillus oryzae expressing a polygalacturonase gene from A. tubingensis Mosseray | GRN 982 (in PDF, 4.0 MB) |
|
981 | Sterol esterase enzyme preparation produced by Trichoderma reesei expressing a gene encoding sterol esterase from Melanocarpus albomyces | GRN 981 (in PDF 3.4 MB) |
|
980 | Dry whole milk |
GRN 980 |
FDA has no questions (in PDF 124 KB) |
979 | Pectin esterase enzyme preparation produced by Aspergillus oryzae expressing a pectin esterase gene from A. tubingensis | GRN 979 with Amendments (in PDF 2.7 MB) |
FDA has no questions (in PDF 143 KB) |
978 | Hydrolyzed aqueous olive pulp extract | GRN 978 with Amendment (in PDF, 4.1 MB) |
FDA has no questions (in PDF 256 KB) |
977 | D-tagatose produced via novel enzymatic cascade | GRN 977 with Amendment (in PDF, 4.0 MB) |
FDA has no questions (in PDF 152.32 KB) |
976 | Sodium hyaluronate | GRN 976 (in PDF 5.0 MB) |
|
975 | Maltogenic alpha-amylase enzyme preparation produced by Bacillus licheniformis carrying the gene coding for maltogenic alpha-amylase from Geobacillus stearothermophilus | GRN 975 (in PDF 484 KB) |
|
974 | Maltogenic alpha-amylase enzyme preparation by Bacillus subtilis | GRN 974 (in PDF 1.8 MB) |
|
973 | Maple wood fiber | GRN 973 (in PDF 3.1 MB) GRN 973 with Amendment (in PDF, 2.2 MB) |
FDA ceased to evaluate (in PDF 169 KB) |
972 | Pectin hydrolysate from carrot pomace | GRN 972 (in PDF 1.8 MB) |
|
971 | Bacillus clausii strain 088AE spore preparation | GRN 971 (in PDF 1.43 MB) |
|
970 | Enzyme-modified steviol glycosides | GRN 970 (in PDF 4.5 MB) |
|
969 | Bacillus subtilis "Bss-19" spore preparation | GRN 969 with Amendment (in PDF 4.8 MB) |
FDA has no questions (in PDF 226 KB) |
967 | Soluble egg-white protein produced by Pichia pastoris strain "DFB-003" | GRN 967 (in PDF 23.13 MB) GRN 967 with Amendment (in PDF 2.1 MB) |
FDA has no questions (in PDF 306 KB) |
966 | Preparations containing three to eight bacteriophages specific to Campylobacter jejuni | GRN 966 (in PDF 13.5 MB) |
FDA has no questions (in PDF 313 KB) |
965 | Arabinase enzyme preparation produced by Aspergillus tubingensis | GRN 965 (in PDF 1.8 MB) |
FDA has no questions (in PDF 500 KB) |
964 | Lysophospholipase enzyme preparation from Aspergillus niger produced by Trichoderma reesei | GRN 964 (in PDF 1.9 MB) GRN 964 with Amendment (in PDF 1.5 MB) |
FDA has no questions (in PDF 158 KB) |
963 | Fungal oil (≥40% arachidonic acid) from Mortierella alpine | GRN 963 (in PDF 17.3 MB) GRN 963 with Amendment (in PDF 1.1 MB) |
FDA has no questions (in PDF 424 KB) |
962 | Rice bran wax | GRN 962 (in PDF 11.0 MB) |
|
961 | Beta-glucan derived from Agrobacterium sp. CCTCC No. M2010020 | GRN 961 with Amendment (in PDF 5.1 MB) |
FDA ceased to evaluate (in PDF 245.81 KB) |
960 | Hypromellose acetate succinate | GRN 960 (in PDF 4.9 MB) |
|
959 | Iron milk proteinate | GRN 959 (in PDF 1.9 MB) |
FDA has no questions (in PDF 213 KB) |
958 | Fungal oil (≥40% arachidonic acid) from Mortierella alpina strain AF | GRN 958 with Amendment (in PDF 1.6 MB) |
FDA ceased to evaluate (in PDF 91 KB) |
957 | Lactobacillus johnsonii strain ATCC PTA-124205 | GRN 957 (in PDF 15 MB) |
|
956 | Bacillus subtilis PLSSC (ATCC SD 7280) | GRN 956 (in PDF 1.3 MB) |
|
955 | Bacillus subtilis strain BS-MB40 PTA-122264 spore preparation | GRN 955 with Amendment (in PDF 3 MB) |
FDA has no questions (in PDF 244 KB) |
954 | Fibrillated cellulose | GRN 954 (in PDF 2.4 MB) |
|
953 | Lactobacillus plantarum strain CECT 7527, CECT 7528 and CECT 7529 | GRN 953 Amendment (in PDF 4.16 MB) |
FDA has no questions (in PDF 279 KB) |
952 | Bifidobacterium animalis subsp. lactis strain AD011 | GRN 952 with Amendment (in PDF 3.09 MB) |
FDA has no questions (in PDF 158.91KB) |
951 | 3-fucosyllactose | GRN 951 with Amendments (in PDF 5.7 MB) |
FDA has no questions (in PDF 272 KB) |
950 | Bifidobacterium longa subsq. infantis DSM 33361 | GRN 950 Part 1 (in PDF 11.5 MB) GRN 950 Part 2 (in PDF 8.9 MB) GRN 950 Part 3 with Amendment (in PDF 8.11 MB) |
FDA has no questions (in PDF 281 KB) |
949 | Bacillus coagulans strain DSM 17654 | GRN 949 (in PDF 21.4 MB) |
FDA has no questions (in PDF 556 KB) |
948 | Enzyme-treated pea protein | GRN 948 (in PDF 1.9 MB) |
|
947 | Cacao pulp, juice and juice concentrate | GRN 947 (in PDF 2.93 MB) |
FDA has no questions (in PDF 145 KB) |
946 | Lactobacillus plantarum strain DSM 33452 | GRN 946 with Amendment (in PDF 3.7 MB) |
FDA has no questions (in PDF 91 KB) |
945 | Fungal protein from Fusarium sp. mycelia | GRN 945 (in PDF 2.7 MB) |
|
944 | Rice protein hydrolysate | GRN 944 with Amendment (in PDF 4.6 MB) |
FDA has no questions (in PDF 280 KB) |
943 | Citrus fiber from the peels of oranges, lemons or limes | GRN 943 (in PDF 3.5 MB) |
|
942 | Whey permeate | GRN 942 (in PDF 919 KB) |
FDA ceased to evaluate (in PDF 188 KB) |
941 | Oat polar lipid extract | GRN 941 (in PDF 3.7 MB) |
FDA ceased to evaluate (in PDF 124 KB) |
940 | Phospholipase A2 enzyme from Sus scrota (wild pig) produced by Yarrowia lipolytica | GRN 940 (in PDF 6.1 MB) |
|
939 | Sunflower lecithin | GRN 939 Part 1 (in PDF 10.2 MB) GRN 939 Part 2 with Amendment (in PDF 18.8 MB) |
FDA has no questions (in PDF 109 KB) |
938 | Pichia kluyveri DSM 33235 | GRN 938 (in PDF 7.6 MB) |
FDA has no questions (in PDF 147 KB) |
937 | Staphylococcus carnosus DSM 25010 | GRN 937 (in PDF 3.5 MB) |
FDA has no questions (in PDF 189 KB) |
936 | Leuconostoc carnosum DSM 32756 | GRN 936 (in PDF 1.8 MB) |
FDA has no questions (in PDF 212 KB) |
935 | L-carnitine-L-tartrate | GRN 935 (in PDF 3.2 MB) |
FDA ceased to evaluate (in PDF 242 KB) |
934 | Algal oil (>35% docosahexanoic acid (DHA)) derived from Schizochytrium sp. strain CABIO-A-2 | GRN 934 (in PDF 2.0 MB) |
FDA has no questions (in PDF 214 KB) |
933 | Algal oil (>36% docosahexaenoic acid) from Schizochytrium sp. strain DHF | GRN 933 (in PDF 5.1 MB) |
FDA has no questions (in PDF 757.41 KB) |
932 | 2'-Fucosyllactose | GRN 932 (in PDF 10.0 MB) GRN 932 with Amendment (in PDF 3.6 MB) |
FDA has no questions (in PDF, 223 KB) |
931 | Creatine monohydrate | GRN 931 (in PDF 3.1 MB) |
FDA has no questions (in PDF 437 KB) |
930 | Silk protein derived from bombyx cocoons | GRN 930 Part 1 (in PDF 18 MB) GRN 930 Part 2 (in PDF 4.5 MB) GRN 930 Part 3 (in PDF 6.8 MB) |
FDA ceased to evaluate (in PDF 125 KB) |
929 | 2'-fucosyllactose | GRN 929 (in PDF 3.6 MB) GRN 929 with Amendment (in PDF 7 MB) |
FDA has no questions (in PDF 267 KB) |
928 | Dried Saccharomyces cerevisiae yeast fermentate | GRN 928 (in PDF 12 MB) GRN 928 with Amendment (in PDF 3.7 MB) |
FDA has no questions (in PDF 248 KB) |
927 | Polyvinyl alcohol | GRN 927 (in PDF 4.0 MB GRN 927 with Amendment (in PDF 5.2 MB) |
FDA has no questions (in PDF 205.85 KB) |
926 | Soluble rice flour | GRN 926 (in PDF 6.32 MB) |
FDA has no questions (in PDF 434 KB) |
925 | 3'-Fucosyllactose | GRN 925 (in PDF 4.13 MB) |
FDA has no questions (in PDF 190 KB) |
924 | 2'-Fucosyllactose | GRN 924 with Amendment (in PDF 2.4 MB) |
FDA ceased to evaluate (in PDF 242 KB) |
923 | Lacto-N-neotetraose | GRN 923 with Amendment (in PDF 2.3 MB) |
FDA has no questions (in PDF 187 KB) |
922 | 6'-sialyllactose sodium salt | GRN 922 with Amendment (in PDF 1.69 MB) |
FDA has no questions (in PDF 243 KB) |
921 | 3'-sialyllactose sodium salt | GRN 921 (in PDF 2.2 MB) |
FDA has no questions (in PDF 771 KB) |
920 | Thaumatin II | GRN 920 (in PDF 5.8 MB) |
FDA has no questions (in PDF 170 KB) |
919 | Lacto-N-neotetraose | GRN 919 (in PDF 1.4 MB) |
FDA has no questions (in PDF 353 KB) |
918 | Partially defatted almond protein flour | GRN 918 (in PDF 1.4 MB) |
|
917 | Preparation containing three bacterial phages specific to Salmonella | GRN 917 (in PDF 3.1 MB) |
FDA has no questions (in PDF 539.77 KB) |
916 | Dihydroquercetin | GRN 916 with Amendment (in PDF 11 MB) |
FDA has no questions (in PDF 245 KB) |
915 | Calcium L-methylfolate | GRN 915 (in PDF 3.8 MB) |
FDA has no questions (in PDF 217 KB) |
914 | Alpha-linolenic acid diacylglycerol | GRN 914 with Amendment (in PDF 3.9 MB) |
FDA has no questions (in PDF 175 KB) |
913 | Algal oil (minimum 35% DHA) | GRN 913 (in PDF 4.1 MB) |
FDA has no questions (in PDF 906 KB) |
912 | Trehalose | GRN 912 (in PDF 2.5 MB) |
FDA ceased to evaluate (in PDF 140 KB) |
911 | Rebaudioside I | GRN 911 (in PDF 14.6 MB) |
FDA has no questions (in PDF 208 KB) |
910 | Thaumatin II produced in Nicotiana benthamiana | GRN 910 (in PDF 2.8 MB) |
FDA has no questions (in PDF 541 KB) |
909 | Whey protein containing 41% alpha-lactalbumin | GRN 909 Amendment (in PDF 1.1 MB) |
FDA ceased to evaluate (in PDF 123 KB) |
908 | Lipase from Penicillium camemberti | GRN 908 Amendment (in PDF 2.1 MB) |
FDA has no questions (in PDF 184 KB) |
907 | Wheat seed oil | GRN 907 (in PDF 10.45 MB) |
FDA has no questions (in PDF 593 KB) |
906 | Wheat polar lipids | GRN 906 (in PDF 3.8 MB) |
FDA has no questions (in PDF 518 KB) |
905 | Bacilllus subtilis SG188 | GRN 905 (in PDF 4.4 MB) |
FDA has no questions (in PDF 659 KB) |
904 | Fungal protein from fermented Fusarium sp. mycelia |
GRN 904 Amendment |
FDA has no questions (in PDF 956 KB) |
903 | Quillaia extract type 2 | GRN 903 (in PDF 2.4 MB) GRN 903 Amendment (in PDF 8.4 MB) |
FDA has no questions (in PDF 194 KB) |
902 | Neohesperidin dihydrochalcon | GRN 902 (in PDF 9 MB) |
FDA has no questions (in PDF 408 KB) |
901 | Glucosyl hesperidin |
GRN 901
|
FDA has no questions (in PDF 670 KB) |
900 | Corn oil | GRN 900 (in PDF 5.2 MB) |
FDA has no questions (in PDF 539 KB) |
899 | Citric acid esters of mono- and diglycerides | GRN 899 (in PDF 2.1 MB) |
FDA has no questions (in PDF 624 KB) |
898 | Dried milk fat |
GRN 898 |
FDA has no questions (in PDF 650 KB) |
897 | 2'-O-fucosyllactose | GRN 897 (in PDF 1.8 MB) |
FDA has no questions (in PDF 715 KB) |
896 | Alpha-galacto-oligosaccharides | GRN 896 with Amendment (in PDF 5.9 MB) |
FDA has no questions (in PDF 202 KB) |
895 | Lacto-N-neotetraose | GRN 895 (in PDF 3.1 MB) |
FDA has no questions (in PDF 858 KB) |
894 | White mulberry leaf extract | GRN 894 (in PDF 6 MB) |
FDA ceased to evaluate (in PDF 200 KB) |
893 | Allulose | GRN 893 (in PDF 9 MB) GRN 893 with Amendments (in PDF 10.6 MB) |
FDA ceased to evaluate (in PDF 58 KB) |
892 | Refined shea butter | GRN 892 (in PDF 11.8 MB) |
FDA ceased to evaluate (in PDF 162 KB) |
891 | Cellulase produced by Trichoderma reesei | GRN 891 with Amendments (in PDF 2.1 MB) |
FDA has no questions (in PDF 512 KB) |
890 | Corn oil derived from distillers grains |
GRN 890 Part 1
|
FDA ceased to evaluate (in PDF 189 KB) |
889 | Wheat germ extract | GRN 889 (in PDF 8.4 MB) |
FDA ceased to evaluate (in PDF 236 KB) |
888 | Preparation containing three bacterial phages specific to Salmonella | GRN 888 (in PDF 8.3 MB) |
FDA ceased to evaluate (in PDF 36 KB) |
887 | Menaquinone-7 | GRN 887 (in PDF 9 MB) |
FDA has no questions (in PDF 472 KB) |
886 | Mixture of monoacylglycerides derived from grape seed | GRN 886 (in PDF 2.6 MB) |
FDA has no questions (in PDF 514 KB) |
885 | Vinyl Acetate-Vinyl Laurate Copolymers (VAVLP) as components of Chewing Gum Base | GRN 885 (in PDF 2.2 MB) |
FDA has no questions (in PDF 451 KB) |
884 | Rice bran extract | GRN 884 (in PDF 11.8 MB) |
FDA has no questions (in PDF 518 KB) |
883 | Ilex guayusa leaf hydroethanolic extract | GRN 883 (in PDF 18.7 MB) |
FDA has no questions (in PDF 514 KB) |
882 | Rebaudioside M | GRN 882 (in PDF 1.4 MB) |
FDA has no questions (in PDF 479 KB) |
881 | 6'-sialyllactose sodium salt | GRN 881 (in PDF 4.5 MB) |
FDA has no questions (in PDF 561 KB) |
880 | 3'-sialyllactose sodium salt | GRN 880 (in PDF 4.6 MB) |
FDA has no questions (in PDF 557 KB) |
879 | Fava bean protein | GRN 879 (in PDF 6 MB) |
FDA has no questions (in PDF 502 KB) |
878 | Glucosylated steviol glycosides | GRN 878 (in PDF 16 MB) |
FDA has no questions Correction Letter |
877 | Bifidobacterium longum BB536 | GRN 877 (in PDF 5.2 MB) |
FDA has no questions (in PDF 74 KB) |
876 | Hydroxytyrosol | GRN 876 with Amendment (in PDF 4.4 MB) |
FDA has no questions (in PDF 88 KB) |
875 | Bifidobacterium animalis subsp. lactis AD011 | GRN 875 (in PDF 3 MB) |
FDA ceased to evaluate (in PDF 258 KB) |
874 | Corn protein | GRN 874 (in PDF 3 MB) |
FDA ceased to evaluate (in PDF 44 KB) |
873 | Cranberry extract | GRN 873 (in PDF 4 MB) |
FDA has no questions (in PDF 567 KB) |
872 | Bifidobacterium animalis subsp. lactic UABla-12 | GRN 872 (in PDF 3.4 MB) |
FDA has no questions (in PDF 61 KB) |
871 | Lactobacillus acidophilus DDS-1 | GRN 871 (in PDF 4.0 MB) |
FDA has no questions (in PDF 49 KB) |
870 | Ilex guayusa leaf hydroethanolic extract | GRN 870 (in PDF 20 MB) |
FDA has no questions (in PDF 550 KB) |
869 | Ilex guayusa leaf extract | GRN 869 (in PDF 20 MB) |
FDA has no questions (in PDF 550 KB) |
868 | Coffee fruit extract | GRN 868 (in PDF 3 MB) |
FDA has no questions (in PDF 556 KB) |
867 | Rebaudioside M | GRN 867 (in PDF 1.8 MB) |
FDA ceased to evaluate (in PDF 35 KB) |
866 | Lipase from Penicillium camemberti | GRN 866 (in PDF 653 KB) |
FDA ceased to evaluate (in PDF 257 KB) |
865 | Lactobacillus acidophilus NCFM | GRN 865 (in PDF 9.33 MB) |
FDA has no questions (in PDF 761 KB) |
864 | Bacillus coagulans SNZ 1969 spore preparation | GRN 864 (in PDF 8.3 MB) |
FDA has no questions (in PDF 560 KB) |
863 | B-lactoglobulin produced by Trichoderma reesei | GRN 863 (in PDF 5.2 MB) |
FDA has no questions (in PDF 637 KB) |
862 | Algal oil (40% docosahexaenoic acid) from Schizochytrium sp. strain ONC-T18 | GRN 862 (in PDF 18.26 MB) |
FDA has no questions (in PDF 748 KB) |
861 | Pullulanase from Bacillus deramificansproduced in Bacillus subtilis | GRN 861 (in PDF 1.3 MB) |
FDA has no questions (in PDF 605 KB) |
860 | Algal oil (36% docosahexaenoic acid) from Schizochytrium sp. strain DHF | GRN 860 (in PDF 8.6 MB) |
FDA ceased to evaluate (in PDF 35 KB) |
859 | 2'-fucosyllactose | GRN 859 (in PDF 13 MB) |
FDA ceased to evaluate (in PDF 248 KB) |
858 | Glucosylated steviol glycosides | GRN 858 Part 1 (in PDF 1.5 MB) GRN 858 Part 2 (in PDF 9 MB) GRN 858 Part 3 (in PDF 6 MB) |
FDA has no questions (in PDF 86 KB) |
857 | Phospholipase A1 produced by Aspergillus niger | GRN 857 (in PDF 1.8 MB) |
FDA has no questions (in PDF 465 KB) |
856 | Bifidobacterium animalis subsp. lactis strain BB-12 | GRN 856 (in PDF 10.94 MB) |
FDA has no questions (in PDF 63 KB) |
855 | Bifidobacterium animalis ssp. lactis strain R0421 | GRN 855 (in PDF 5.0 MB) |
FDA has no questions (in PDF 634 KB) |
854 | Inulin from Agave tequilana | GRN 854 (in PDF 28.5 MB) |
FDA has no questions (in PDF 2 MB) |
853 | Lysozyme produced by Trichoderma reesei | GRN 853 (in PDF 1 MB) |
FDA has no questions (in PDF 552 KB) |
852 | 2-fucosyllactose | GRN 852 (in PDF 9.4 MB) |
FDA has no questions (in PDF 108 KB) |
851 | Pea protein | GRN 851 (in PDF 1.6 MB) |
FDA has no questions (in PDF 601 KB) |
850 | Shea olein | GRN 850 (in PDF 13.4 MB) |
FDA has no questions (in PDF 610 KB) |
849 | Inulin from artichoke | GRN 849 (in PDF 8.56 MB) |
FDA has no questions (in PDF 129 KB) |
848 | Pea and rice protein fermented by Shitake mycelia | GRN 848 (in PDF 7.6 MB) |
FDA has no questions (in PDF 487 KB) |
846 | Rebaudioside M | FDA has no questions (in PDF 102 KB) |
|
847 | Lactobacillus plantarum ECGC 13110402 | GRN 847 (in PDF 4.7 MB) |
FDA has no questions (in PDF 63 KB) |
846 | Rebaudioside M | GRN 846 (in PDF 4 MB) |
|
845 | Lactobacillus rhamnosus LGG | GRN 845 (in PDF 7.6 MB) |
FDA has no questions (in PDF 121 KB) |
844 | Algal oil (55% docosahexaenoic acid) from Schizochytrium sp. strain FCC-3204 | GRN 844 (in PDF 3.4 MB) |
FDA has no questions (in PDF 105 KB) |
843 | Algal oil (35% docosahexaenoic acid) from Schizochytrium sp. strain FCC-1324 | GRN 843 (in PDF 4.9 MB) |
FDA has no questions (in PDF 85 KB) |
842 | Maltogenic alpha-amylase | GRN 842 (in PDF 1.03 MB) |
FDA has no questions (in PDF 715 KB) |
841 | Saccharomyces cerevisiae expressing L-lactate dehydrogenase from Rhizopus oryzae | GRN 841 (in PDF 2.7 MB) |
FDA has no questions (in PDF 604 KB) |
840 | Lactobacillus paracasei strain F19 | GRN 840 (in PDF 3 MB) |
FDA has no questions (in PDF 76 KB) |
839 | Purified steviol glycosides | GRN 839 (in PDF 3.9 MB) |
FDA has no questions (in PDF 77 KB) |
838 | Purified steviol glycosides | GRN 838 (in PDF 4.5 MB) |
FDA has no questions (in PDF 83 KB) |
837 | Hydroxytyrosol | GRN 837 (in PDF 2.7 MB) |
FDA ceased to evaluate (in PDF 54 KB) |
836 | Algal oil (50-60% docosahexaenoic acid) from Schizochytrium sp. HS01 | GRN 836 (in PDF 2.3 MB) |
FDA has no questions (in PDF 74 KB) |
835 | Ilex guayusa leaf extract | GRN 835 (in PDF 6.8 MB) |
FDA ceased to evaluate (in PDF 35.24 KB) |
834 | Preparation containing bacterial phages specific to shiga-toxin Escherichia coli | GRN 834 (in PDF 11.69 MB) |
FDA has no questions (in PDF 91 KB) |
833 | Lacto-N-tetraose | GRN 833 (in PDF 11MB) |
FDA has no questions (in PDF 105 KB) Correction Letter (in PDF 701 KB) |
832 | Acid prolyl endopeptidase produced by Aspergillus niger | GRN 832 (in PDF 2.6 MB) |
FDA has no questions (in PDF 284.21 KB) |
831 | Bacillus subtilis DE111 | GRN 831 (in PDF 6.4 MB) |
FDA has no questions (in PDF 73 KB) |
830 | Chicory flour | GRN 830 (in PDF 1.51 MB) |
FDA ceased to evaluate (in PDF 53.77 KB) |
829 | Dried biomass of Aspergillus oryzae fermented with minerals | GRN 829 (in PDF 1.3 MB) |
FDA has no questions (in PDF 110 KB) Additional correspondence (in PDF 104 KB) |
828 | D-psicose | GRN 828 (in PDF 1.4 MB) |
FDA has no questions (in PDF 550 KB) |
827 | Preparation containing three bacterial phages specific to Escherichia coli serotypes | GRN 827 (in PDF 20 MB) |
FDA has no questions (in PDF 75.92 KB) (in PDF 447 KB) |
826 | Dihydroquercetin | GRN 826 (in PDF 15.4 MB) |
FDA ceased to evaluate (in PDF 35 KB) |
825 | Beta-galactosidase from Kluyveromyces lactis | GRN 825 (in PDF 5.0 MB) |
FDA has no questions (in PDF 64 KB) |
824 | Bacteriocin preparations specific to Salmonella | GRN 824 (in PDF 6.7 MB) |
FDA has no questions |
823 | Rebaudioside E | GRN 823 (in PDF 6.2 MB) |
FDA has no questions (in PDF 757 KB) |
822 | Curcumin | GRN 822 (in PDF 4.8 MB) |
FDA has no questions (in PDF 861 KB) |
821 | Glucosylated steviol glycosides | GRN 821 (in PDF 1.6 MB) |
FDA has no questions (in PDF 743 KB) |
820 | Lactobacillus fermentum CECT5716 | GRN 820 (in PDF 3.62 MB) |
GRN 820 (in PDF 35.2 KB) |
819 | Fatty acid ethyl esters from Alaskan Pollock | GRN 819 (in PDF 6 MB) |
FDA has no questions (in PDF 63 KB) |
818 | Isomalto-oligosaccharides | GRN 818 (in PDF 3.83 MB) |
FDA has no questions (in PDF 126.11 KB) |
817 | Serine endopetidase from Melbranchea cinnamomea produced in Trichaderma reesei | GRN 817 (in PDF 3.5 MB) |
FDA has no questions (in PDF 67.82 KB) |
816 | Xylooligosaccharides from sugarcane | GRN 816 (in PDF 8.3 MB) |
GRN 816 (in PDF 68.2 KB) |
815 | 2' -fucosyllactose and difucosyllactose | GRN 815 (in PDF 3.3 MB) |
FDA has no questions Correction Letter Correction Letter |
814 | Bifidobacterium bifidum BGN4 | GRN 814 (in PDF 2.5 MB) |
FDA has no questions (in PDF 78 KB) |
813 | Bifidobacterium longum BORI | GRN 813 (in PDF 1.7 MB) |
FDA has no questions (in PDF 82 KB) |
812 | Rebaudioside M | GRN 812 (in PDF 8 MB) |
FDA has no questions (in PDF 659 KB) |
811 | Phospholipase A1 produced by Aspergillus oryzae | GRN 811 (in PDF 1.5 MB) |
FDA has no questions (in PDF 64 KB) |
810 | Lactobacillus paracasei subsp. paracasei strain F-19e | GRN 810 (in PDF 1.7 MB |
GRN 810 (in PDF 178 KB) |
809 | Fractionated whey protein concentrate containing 41% alphalactalbumin | GRN 809 (in PDF 6.2 MB) |
FDA has no questions (in PDF 315.2 KB) |
808 | Lipase from Aspergillus tubingensis produced in Trichoderma reesei | GRN 808 (in PDF 2.4 MB) |
FDA has no questions (in PDF 79.73 KB) |
807 | Streptococcus salivarius M18 | GRN 807 (in PDF 2.4 MB) |
Correction letter issued June 6, 2019 (in PDF 66 KB) |
806 | Dolomite | GRN 806 (in PDF 747.31 KB) |
GRN 806 (in PDF 275 KB) |
805 | Apple peel powder | GRN 805 (in PDF 5.0 MB) |
FDA has no questions (in PDF 522 kB) |
804 | Pea protein | GRN 804 (in PDF 5 MB) |
FDA has no questions (in PDF 94 KB) |
803 | Pea protein | GRN 803 (in PDF 1.1 MB) |
FDA has no questions (in PDF 91 KB) |
802 | Endolysin | GRN 802 (in PDF 5.5 MB) |
GRN 802 (in PDF 294 KB) |
801 | Chymosin enzyme from Camelus dromendarius produce in Aspergillus niger | GRN 801 (in PDF 15 MB) |
FDA has no questions (in PDF 71 KB) |
800 | Gamma-oryzanol | GRN 800 Part 1 (in PDF 8 MB) GRN 800 Part 2 (in PDF 17 MB) |
FDA has no questions (in PDF 628 KB) |
799 | Rebaudioside M | GRN 799 (in PDF 1.2 MB) |
FDA has no questions (in PDF 112 KB) |
798 | Saccharomyces cerevisiae strain yBBS002 | GRN 798 (in PDF 5.6 MB) |
FDA has no questions (in PDF 73.19 KB) |
797 | Fructooligosaccharides | GRN 797 (in PDF 16 MB |
FDA has no questions (in PDF 450 KB) |
796 | Orange extract (85% hesperidin) | GRN 796 (in PDF 11 MB) |
FDA has no questions (in PDF 459 KB) |
795 | Purified steviol glycosides | GRN 795 (in PDF 10 MB) |
FDA has no questions (in PDF 106 KB) |
794 | Shiitake, pea, and rice protein fermented with Lentinula edodes | GRN 794 (in PDF 11.9 MB) |
FDA ceased to evaluate this notice (in PDF 57 KB) |
793 | Cultured corn starch fermented by Corynebacterium stationis | GRN 793 (in PDF 5.1 MB) |
GRN 793 (in PDF 171 KB) |
792 | Cultured corn starch fermented by Corynebacterium glutamicum | GRN 792 (in PDF 7.6 MB) |
GRN 792 (in PDF 160 KB) |
791 | Urolithin A | GRN 791 (in PDF 2.3 MB) |
FDA has no questions (in PDF 61 KB) |
790 | Steviol glycosides | GRN 790 (in PDF 4 MB) |
FDA has no questions (in PDF 448 KB) |
789 | Erythritol | GRN 789 Part 1 (in PDF 13.8 MB) GRN 789 Part 2 (in PDF 13.1 MB) |
FDA has no questions (in PDF 80 KB) |
788 | Pea protein | GRN 788 (in PDF 7.3 MB) |
FDA has no questions (in PDF 246 KB) |
787 | Quinoa sprout powder | GRN 787 (in PDF 12.9 MB) |
FDA has no questions (in PDF 94 KB) |
786 | Calcium propionate | GRN 786 (in PDF 2.8 MB) |
FDA has no questions (in PDF 70 KB) |
785 | Calcium chloride | GRN 785 (in PDF 1.3 MB) |
FDA has no questions (in PDF 74 KB) |
784 | Siraitia grosvenorii Swingle | GRN 784 (in PDF 3 MB) |
FDA has no questions (in PDF 664 KB) |
783 | Triacylglycerol lipase from Rhizopus oryzae produced in Aspergillus niger | GRN 783 Part 1 (in PDF 2.7 MB) GRN 783 Part 2 (in PDF 17 MB) GRN 783 Part 3 (in PDF 5.9 MB) GRN 783 Part 4 (in PDF 6.4 MB) |
Correction letter (in PDF 75 KB) |
782 | L-arabinose | GRN 782 (in PDF 9.02 MB) |
FDA has no questions (in PDF 47 KB) |
781 | Alpha-tocopherol (fruit and vegetable derived) | GRN 781 (in PDF 3 MB) |
FDA has no questions (in PDF 1 MB) |
780 | Rebaudioside M | GRN 780 (in PDF 1 MB) |
FDA has no questions (in PDF 115 KB) |
779 | Isomalto-oligosaccharide mixture | GRN 779 (in PDF 12 MB) |
FDA has no questions (in PDF 89 KB) |
778 | Hemp seed oil | GRN 778 (in PDF 19 MB) GRN 778 Amendment (in PDF 352 kB) |
FDA has no questions (in PDF 429 KB) |
777 | Algal oil (55% docosahexaenoic acid) from Schizochytrium sp. FCC-3204 | GRN 777 (in PDF 13.4 MB) |
FDA has no questions (in PDF 230 KB) |
776 | Algal oil (35% docosahexaenoic acid) from Schizochytrium sp. FCC-1324 | GRN 776 (in PDF 1.58 MB) |
FDA has no questions (in PDF 570 KB) |
775 | colicin proteins produced in Nicotiana benthamiana (colicin preparations) | GRN 775 (in PDF 3.34 MB) |
FDA has no questions (in PDF 77 KB) |
774 | Glutaminase from Bacillus licheniformis produced in Bacillus licheniformis | GRN 774 (in PDF 1.28 MB) |
FDA has no questions (in PDF 73 KB) |
773 | Dried biomass of Chlamydomonas reinhardtii | GRN 773 (in PDF 4.99 MB) |
Correspondence Correction (in PDF 149 KB) |
772 | Palmitoylated green tea catechins | GRN 772 (in PDF 1.68 MB) |
FDA has no questions (in PDF 63 KB) |
771 | Hemp seed protein | GRN 771 Part 1 (in PDF 4.4 MB) GRN 771 part 2 (in PDF 14.9MB) GRN 771 Amendment (in PDF 352 KB) |
FDA has no questions (in PDF 480 KB) |
770 | Potassium polyaspartate | GRN 770 (in PDF 1.28 MB) |
FDA has no questions (in PDF 786 KB) |
769 | Vitamin C (fruit and vegetable derived) | GRN 769 (in PDF 770 KB) |
FDA has no questions (in PDF 72 KB) |
768 | Stevia leaf extract | GRN 768 (in PDF 2 MB) |
FDA has no questions (in PDF 100 KB) |
767 | Polyvinyl alcohol | GRN 767 (in PDF 502.88 KB) |
FDA has no questions (in PDF 57 KB) |
766 | 3’-sialyllactose sodium salt | GRN 766 (in PDF 919 KB) |
FDA has no questions |
765 | Hulled hemp seed | GRN 765 (in PDF 19 MB) GRN 765 Amendment (in PDF 352 kB) |
FDA has no questions (in PDF 273 KB) |
764 | Rebaudioside D | GRN 764 (in PDF 8.46 MB) |
FDA has no questions (in PDF 111 KB) |
763 | Alpha-lactalbumin | GRN 763 (in PDF 1.9 MB) |
FDA has no questions (in PDF 106 KB) |
762 | Carnobacterium divergens M35 preparation | GRN 762 (in PDF 5.4 MB) |
FDA has no questions (in PDF 32 KB) |
761 | Esterified propoxylated glycerol | GRN 761 (in PDF 3.2 MB) |
FDA has no questions (in PDF 106 KB) |
760 | Lactobacillus curvatus DSM 18775 | GRN 760 (in PDF 3.7 MB) |
FDA has no questions (in PDF 77 KB) |
759 | Steviol glycosides consisting primarily of rebaudioside M produced in Yarrowia lipolytica | GRN 759 (in PDF 3.7 MB) |
FDA has no questions (in PDF 106 KB) |
758 | Lactobacillus helveticus R0052, Bifidobacterium longum ssp. infantis R0033, and Bifidobacterium bifidum R0071 | GRN 758 (in PDF 5 MB) |
FDA has no questions (in PDF 103 KB) |
757 | Escherichia coli O157 | GRN 757 (in PDF 2 MB) |
FDA has no questions (in PDF 59 KB) |
756 | Endo-1,4-beta-glucanase from Trichoderma reesei | GRN 756 (in PDF 3.5 MB) |
FDA has no questions (in PDF 92 KB) |
755 | D-psicose | GRN 755 (in PDF 545 kB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 57 KB) |
754 | Algal oil (87% oleic acid) derived from Prototheca moriformis strain S6697 | GRN 754 (in PDF 15 MB) |
FDA has no questions (in PDF 87 KB) |
753 | Sodium Thiocyanate | GRN 753 (in PDF 6.9 MB) |
FDA has no questions (in PDF 56 KB) |
752 | Preparation containing the bacterial monophages, BP-63 and LVR16-A, specific to Salmonella | GRN 752 (in PDF 2.3 MB) |
FDA has no questions (in PDF 57 KB) |
751 | Maltogenic alpha-amylase from Bacillus stearothermophilus produced in Bacillus subtilis | GRN 751 (in PDF 1.1 MB) |
FDA has no questions (in PDF 228 KB) |
750 | Beta-glucosidase | GRN 750 Part 1 (in PDF 7.7 MB) GRN 750 Part 2 (in PDF 16.4 MB) GRN 750 Part 3 (in PDF 14 MB) GRN 750 Part 4 (in PDF 20 MB) |
FDA has no questions (in PDF 767 KB) |
749 | 2’-O-fucosyllactose | GRN 749 Part 1 (in PDF 10.6 MB) GRN 749 Part 2 (in PDF 12.2 MB) |
FDA has no questions (in PDF 96 KB) |
748 | Tomato powder | GRN 748 (in PDF 3.4 MB) |
FDA ceased to evaluate (in PDF 45 KB) |
747 | Calcium lactate | GRN 747 (in PDF 2.2 MB) |
FDA has no questions (in PDF 76 KB) |
746 | Maltogenic amylase from Geobacillus stearothermophilus produced in Bacillus subtilis | GRN 746 (in PDF 7.1 MB) |
FDA has no questions (in PDF 104 KB) |
745 | Steviol glycosides consisting primarily of rebaudioside M | GRN 745 (in PDF 1 MB) |
FDA has no questions (in PDF 139 KB) |
744 | Steviol glycosides consisting primarily of rebaudioside M | GRN 744 (in PDF 1.9 MB) |
FDA has no questions (in PDF 131 KB) |
743 | β-galactosidase from Papiliotrema terrestris | GRN 743 (in PDF 8.7 MB) |
FDA has no questions (in PDF 69 KB) |
742 | Duckweed (subfamily Lemnoideae) powder | GRN 742 Part 1 (in PDF 9 MB) GRN 742 Part 2 (in PDF 8.7 MB) GRN 742 Part 3 (in PDF 11.5 MB) |
FDA has no questions (in PDF 64 KB) |
741 | Dimethyl ether | GRN 741 (in PDF 403 KB) |
FDA has no questions (in PDF 72 KB) |
740 | Glycolipids from Dacryopinax spathularia | GRN 740 (in PDF 3.7 MB) |
FDA has no questions (in PDF 94 KB) |
739 | Mannanase enzyme from Talaromyces leycettanus produced in Aspergillus niger | GRN 739 (in PDF 622 KB) |
FDA has no questions (in PDF 113 KB) |
738 | Thaumatin | GRN 738 (in PDF 1.8 MB) |
FDA has no questions (in PDF 77 KB) |
737 | Soy leghemoglobin | GRN 737 Part 1 (in PDF 10.1 MB) GRN 737 Part 2 (in PDF 9.2 MB) GRN 737 Part 3 (in PDF 10.4 MB) |
FDA has no questions (in PDF 80 KB) |
736 | Lactobacillus casei subsp. paracasei Lpc-37 | GRN 736 (in PDF 17.6 MB) |
FDA has no questions (in PDF 73 KB) |
735 | 2’-Fucosyllactose | GRN 735 Part 1 (in PDF 15.5 MB) GRN 735 Part 2 (in PDF 16.3 MB) GRN 735 Part 3 (in PDF 10.3 MB), GRN 735 Part 4 (in PDF 14.8 MB) |
FDA has no questions (in PDF 103 KB) |
734 | Ergothionine | GRN 734 (in PDF 18.5 MB) |
FDA has no questions (in PDF 70 KB) |
733 | Purified steviol glycosides | GRN 733 Part 1 (in PDF 9.8 MB) GRN 733 Part 2 (in PDF 15 MB) |
FDA has no questions (in PDF 69 KB) |
732 | Docosahexaenoic acid oil produced in Schizochytrium sp. | GRN 732 (in PDF 5.3 MB) |
FDA has no questions (in PDF 68 KB) |
731 | Docosahexaenoic acid oil produced in Schizochytrium sp. | GRN 731 (in PDF 454 KB) |
FDA has no questions (in PDF 72 KB) |
730 | Arachidonic Acid Oil Produced in Mortierella Alpina | GRN 730 (in PDF 6.8 MB) |
FDA has no questions (in PDF 77 KB) |
729 | Galacto-oligosaccharides | GRN 729 (in PDF 15 MB) |
FDA has no questions (in PDF 112 KB) |
728 | Phospholipase C from Pseudomonas sp. 62186 produced in Bacillus licheniformis | GRN 728 (in PDF 730 KB) |
FDA has no questions (in PDF 47 KB) |
727 | Trehalase from Trichoderma reesei produced in Trichoderma reesei | GRN 727 (in PDF 4.9 MB) |
FDA has no questions (in PDF 61 KB) |
726 | Polyphenol extract from olive | GRN 726 (in PDF 7.5 MB) |
FDA has no questions (in PDF 66 KB) |
725 | Inactivated Bacillus coagulans GBI-30, 6086 | GRN 725 (in PDF 5.2 MB) |
FDA has no questions (in PDF 52 KB) |
724 | Preparation containing six bacterial phages specific to shiga-toxin producing Escherichia coli | GRN 724 (in PDF 4.2 MB) |
FDA has no questions (in PDF 75 KB) |
723 | Benzalkonium chloride | GRN 723 (in PDF 18.6 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 41 KB) |
722 | Lactobacillus plantarum Lp-115 | GRN 722 (in PDF 10.3 MB) |
FDA has no questions (in PDF 67 KB) |
721 | Galacto-oligosaccharides | GRN 721 (in PDF 10 MB) |
FDA has no questions (in PDF 69 KB) |
720 | Rice bran wax | GRN 720 (in PDF 23.4 MB) |
FDA has no questions (in PDF 73 KB) |
719 | Orange pomace | GRN 719 (in PDF 2.1 MB) |
FDA has no questions (in PDF 66 KB) |
718 | Calcium acid pyrophosphate | GRN 718 Amendment (in PDF 1 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 32 KB) |
717 | Short-chain fructo-oligosaccharides | GRN 717 (in PDF 4.1 MB) |
FDA has no questions (in PDF 82 KB) |
716 | Bovine milk osteopontin | GRN 716 Part 1 with Amendment (in PDF 19.9 MB) GRN 716 Part 2 (in PDF 483 KB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 32 KB) |
715 | Rebaudioside D | GRN 715 (in PDF 2.9 MB) |
FDA has no questions (in PDF 69 KB) |
714 | Subtilisin from Bacillus amyloliquefaciens produced in Bacillus subtilis | GRN 714 (in PDF 10.8 MB) |
FDA has no questions (in PDF 53 KB) |
713 | Hydrolyzed pork cartilage | GRN 713 (in PDF 636 KB) |
FDA has no questions (in PDF 65 KB) |
712 | Calcium acetate | GRN 712 (in PDF 11.9 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 44 KB) |
711 | Glucan | GRN 711 (in PDF 1.8 MB) |
FDA has no questions (in PDF 49 KB) |
710 | Basic methacrylate copolymer | GRN 710 (in PDF 414 KB) GRN 710 with Amendments (in PDF 1.0 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 50 KB) |
709 | Pyrroloquinoline quinone disodium salt | GRN 709 (in PDF 1.55 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 79 KB) |
708 | Triacylglycerol lipase from Rhizopus oryzae produced in Aspergillus niger | At the notifier's request, FDA ceased to evaluate this notice (in PDF 52 KB) |
|
707 | Glucose oxidase from Penicillium produced in Trichoderma reesei | GRN 707 (in PDF 22 MB) |
FDA has no questions (in PDF 51 KB) |
706 | Siraitia grosvenorii Swingle (Luo Han Guo) fruit extract | GRN 706 (in PDF 16.6 MB) |
FDA has no questions (in PDF 93 KB) |
705 | Distarch phosphate | GRN 705 (in PDF 21.1 MB) |
FDA has no questions (in PDF 63 KB) |
704 | Corn oil (by-product of ethanol production) | GRN 704 (in PDF 8.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 67 KB) |
703 | Alpha-glucosidase from Aspergillus niger produced by Trichoderma reesi | GRN 703 (in PDF 10 MB) |
FDA has no questions (in PDF 128 KB) |
702 | Purified steviol glycosides | GRN 702 (in PDF 11.5 MB) |
FDA has no questions (in PDF 65 KB) |
701 | Pyrroloquinoline quinone disodium salt | GRN 701 (in PDF 3.7 MB) |
FDA has no questions (in PDF 68 KB) |
700 | Paracoccus carotinifaciens extract containing carotenoids | GRN 700 (in PDF 17 MB) |
FDA has no questions (in PDF 99 KB) |
699 | Trehalase from Myceliophthora sepedonium produced by Aspergillus niger | GRN 699 (in PDF 4.2 MB) |
FDA has no questions (in PDF 67 KB) |
698 | Paramylon isolate from Euglena gracilis | GRN 698 (in PDF 4.7 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 105 KB) |
697 | Dried biomass of Euglena gracilis | GRN 697 (in PDF 4.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 105 KB) |
696 | Dolomite | GRN 696 (in PDF 897 kB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 53 KB) |
695 | Dimethyl ether | GRN 695 (in PDF 1.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 46 KB) |
694 | Pyrroloquinoline quinone disodium salt (PQQ) | GRN 694 (in PDF 6.7 MB) |
FDA has no questions (in PDF 72 KB) |
693 | D-psicose | GRN 693 (in PDF 1.6 MB) |
FDA has no questions (in PDF 97 KB) |
692 | Quinoa sprout extract | GRN 692 (in PDF 1.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 33 KB) |
691 | Bacillus coagulans SANK 70258 spore preparation | GRN 691 (in PDF 14.3 MB) |
FDA has no questions (in PDF 54 KB) |
690 | Fruit and vegetable vitamin extract | GRN 690 with Amendment (in PDF 2.6 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 117 KB) |
689 | Phospholipase C from Bacillus thuringiensis produced in Bacillus licheniformis | GRN 689 (in PDF 870 KB) |
FDA has no questions (in PDF 54 KB) |
688 | Sodium thiocyanate | GRN 688 (in PDF 2.2 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 47 KB) |
687 | Inulin from Agave tequilana | GRN 687 (in PDF 16.5 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 54 KB) |
686 | Curcumin from turmeric (Curcuma longa L.) | GRN 686 (in PDF 5.2 MB) |
FDA has no questions (in PDF 152 KB) |
685 | Lactobacillus plantarum strain 299v | GRN 685 (in PDF 4.8 MB) |
FDA has no questions (in PDF 44 KB) |
684 | Mung bean protein isolate | GRN 684 (in PDF 8.3 MB) |
FDA has no questions (in PDF 119 KB) |
683 | Canola protein isolate | GRN 683 (in PDF 13.6 MB) |
FDA has no questions (in PDF 75 KB) |
682 | Lecithin from canola | GRN 682 (in PDF 7.2 MB) |
FDA has no questions (in PDF 151 KB) |
681 | Dried isomaltulose syrup | GRN 681 (in PDF 7.3 MB) |
FDA has no questions (in PDF 151 KB) |
680 | Alpha-L-arabinofuranosidase from Talaromyces pinophilus produced by Trichoderma reesei | GRN 680 (in PDF 639 kB) |
FDA has no questions (in PDF 101 KB) |
679 | Dealcoholized fermented orange juice | GRN 679 (in PDF 2.2 MB) |
FDA has no questions (in PDF 67 KB) |
678 | Alpha-cyclodextrin | GRN 678 with Amendment (in PDF 9.4 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 49 KB) |
677 | Docosahexaenoic acid oil produced in Schizochytrium sp. | GRN 677 (in PDF 12.3 MB) |
FDA has no questions (in PDF 101 KB) |
676 | Colicin | GRN 676 (in PDF 1.9 MB) |
FDA has no questions (in PDF 90 KB) |
675 | Xylanase enzyme preparation produced by Trichoderma reesei carrying a xylanase gene from Talaromyces leycettanus | GRN 675 (in PDF 776 kB) |
FDA has no questions (in PDF 76 KB) |
674 | Isomalto-oligosaccharides | GRN 674 (in PDF 1.2 MB) |
FDA has no questions (in PDF 160 KB) |
673 | Algal fat derived from Prototheca moriformis (S7737) | GRN 673 (in PDF 15.3 MB) |
FDA has no questions (in PDF 76 KB) |
672 | Preparation containing five bacterial monophages specific to Shigella spp. | GRN 672 (in PDF 1.4 MB) |
FDA has no questions (in PDF 109 KB) |
671 | Galacto-oligosaccharides (GOS) | GRN 671 (in PDF 4 MB) |
At the notifier's request, FDA ceased to evaluate this notice (in PDF 62 KB) |
670 | Inactivated Bacillus coagulans GBI-30, 6086 | GRN 670 (in PDF 325 KB) |
FDA has no questions (in PDF 47 KB) |
669 | Cow's milk-derived lactoferrin | GRN 669 Part 1 (in PDF 9.4 MB) GRN 669 Part 2 (in PDF 18.3 MB) GRN 669 Part 3 (in PDF 9.8 MB) GRN 669 Part 4 (in PDF 14.3 MB) |
FDA has no questions (in PDF 168 KB) |
668 | Sodium formate | GRN 668 (in PDF 2.6 MB) |
FDA has no questions (in PDF 106 KB) |
667 | Rebaudioside M | GRN 667 (in PDF 6.5 MB) |
FDA has no questions (in PDF 115 KB) |
666 | Chondroitin sodium sulfate | GRN 666 (in PDF 4.9 MB) |
FDA has no questions (in PDF 109 KB) |
665 | Lactoperoxidase system | GRN 665 (in PDF 658 kB) |
At the notifier's request, FDA ceased to evaluate this notice |
664 | Alpha-amylase from Cytophaga sp. expressed in Bacillus licheniformis | GRN 664 (in PDF 1 MB) |
FDA has no questions (in PDF 79 KB) |
663 | Distarch phosphate | GRN 663 (in PDF 2.6 MB) |
At the notifier's request, FDA ceased to evaluate this notice |
662 | Glucosylated steviol glycosides (minimum purity 95%) | GRN 662 (in PDF 5.9 MB) |
FDA has no questions |
661 | Fucus vesiculosus concentrate | GRN 661 (in PDF 9.7 MB) |
FDA has no questions (in PDF 85 KB) |
660 | Bacillus coagulans GBI-30, 6086 | GRN 660 (in PDF 3.6 MB) |
FDA has no questions (in PDF 81 KB) |
659 | Lacto-N-neotetraose | GRN 659 with Supplement (in PDF 3.3 MB) |
FDA has no questions Supplemental Reponse Letter (in PDF 267 KB) |
658 | Grapefruit extract | At the notifier's request, FDA ceased to evaluate this notice | |
657 | Glucoamylase from Penicillum oxalicum produced in Aspergillus niger | FDA has no questions | |
656 | Enzyme-modified steviol glycosides |
Supplemental Reponse Letter |
|
655 | Rice bran wax | At the notifier's request, FDA ceased to evaluate this notice | |
654 | Cocoa butter substitute | FDA has no questions | |
653 | Lysophospholipase from Aspergillus nishimurae expressed in Trichoderma reesei. | FDA has no questions | |
652 | Gamma linolenic acid safflower oil | FDA has no questions | |
651 | Phospholipase A1 from Talaromyces leycettanus produced in Aspergillus niger | FDA has no questions | |
650 | 2'-O-fucosyllactose |
Supplemental Response Letter Supplemental Response Letter 2 |
|
649 | β-galactosidase enzyme preparation from Bacillus circulans produced in Bacillus subtilis | FDA has no questions | |
648 | Monoglycerides | FDA has no questions | |
647 | D-psicose | At the notifier's request, FDA ceased to evaluate this notice | |
646 | Pecan shell fiber | FDA has no questions | |
645 | Pullulanase from Bacillus deramificans and Bacillus acidopullulyticus expressed in Bacillus licheniformis | FDA has no questions | |
644 | Non-fat dry goat milk and goat whey protein | FDA has no questions | |
643 | Phosphatidylserine derived from fish | At the notifier's request, FDA ceased to evaluate this notice | |
642 | Camelina oil | FDA has no questions | |
641 | Pyrroloquinoline quinone disodium salt | FDA has no questions | |
640 | Esterified propoxylated glycerol | FDA has no questions | |
639 | Zeaxanthin from marigold | FDA has no questions | |
638 | High purity steviol glycosides (minimum purity 97%) consisting primarily of rebaudioside A | FDA has no questions | |
637 | Phosphatidylserine derived soy lecithin | At the notifier's request, FDA ceased to evaluate this notice | |
636 | Phosphatidylserine derived from sunflower | At the notifier's request, FDA ceased to evaluate this notice | |
635 | Nicotinamide riboside chloride | FDA has no questions | |
634 | Calcium chloride | FDA has no questions | |
633 | Whey protein | FDA has no questions | |
632 | Rebaudioside A from Yarrowia lipolytica | FDA has no questions | |
631 | Triacylglycerol lipase from Fusarium oxysporum produced in Trichoderma reesei | FDA has no questions | |
630 | Preparation containing the bacterial monophages, Fo1a and S16, specific to Salmonella | At the notifier's request, FDA ceased to evaluate this notice | |
629 | Siraitia grosvenorii Swingle (Luo Han Guo) fruit extract | At the notifier's request, FDA ceased to evaluate this notice | |
628 | endo-1,4-beta-xylanase from Trichoderma reesei | FDA has no questions | |
627 | Siraitia grosvenorii Swingle (Luo Han Guo) fruit juice concentrate | FDA has no further questions | |
626 | Steviol glycosides produced in Saccharomyces cerevisiae | FDA has no questions | |
625 | Pyrroloquinoline quinone disodium salt | FDA has no questions | |
624 | D-allulose 3-epimerase from Arthrobacter globiformis M30 produced in Escherichia coli | FDA has no questions | |
623 | Fructooligosaccharides | FDA has no questions | |
622 | Emulsified fish oil | At the notifier's request, FDA ceased to evaluate this notice | |
621 | Emulsified algal oil | At the notifier's request, FDA ceased to evaluate this notice | |
620 | Galacto-oligosaccharides | FDA has no questions | |
619 | Purified steviol glycosides | FDA has no questions | |
618 | Purified seawater | FDA has no questions | |
617 | α-amylase from Cytophaga sp. produced in Bacillus licheniformis | At the notifier's request, FDA ceased to evaluate this notice | |
616 | High-amylose cornstarch acetate | FDA has no questions | |
615 | High-amylose cornstarch | FDA has no questions | |
614 | Chromium polynicotinate | FDA has no questions | |
613 | Apple peel powder | At the notifier's request, FDA ceased to evaluate this notice | |
612 | Fractionated whey protein isolate containing cow’s milk derived lactoferrin, lactoperoxidase, and transforming growth factor β2 | At the notifier's request, FDA ceased to evaluate this notice | |
611 | Fractionated whey protein isolate containing cow’s milk derived lactoferrin, lactoperoxidase, and transforming growth factor β2 | At notifier's request, FDA ceased to evaluate the notice | |
610 | Isomaltodextrin | FDA has no questions | |
609 | Rice protein | Additional letter (in PDF 81 KB) FDA has no questions |
|
608 | Pea protein concentrate | FDA has no questions | |
607 | Glucosylated steviol glycosides (minimum purity 80%) |
Supplemental letter |
|
606 | Vinyl acetate-vinyl laurate copolymers | FDA has no questions | |
605 | Fructo-oligosaccharides | FDA has no questions | |
604 | Baker's Yeast (Saccharomyces cerevisiae) expressing asparaginase II | FDA has no questions | |
603 | Preparation containing the bacterial monophages, BP-63 and BP-12, specific to Salmonella | FDA has no questions | |
602 | N-acetyl-D-neuraminic acid | FDA has no questions | |
601 | Bacillus coagulans SBC37-01 spore preparation | FDA has no questions | |
600 | Hydroxytyrosol | FDA has no questions | |
599 | Citrus fiber | FDA has no questions | |
598 | Thermolysin enzyme preparation derived from Geobacillus stearothermophilus | FDA has no questions | |
597 | Bacillus coagulans SNZ1969 spores preparation | FDA has no questions | |
596 | Breadfruit flour | FDA has no questions | |
595 | gamma-aminobutyric acid |
At the notifier's request, FDA ceased to evaluate this notice |
|
594 | α-amylase from Geobacillus stearothermophilus produced in Bacillus licheniformis | FDA has no questions | |
593 | Colicin preparations | FDA has no questions | |
592 | β-glucanase from Bacillus subtilis | FDA has no questions | |
591 | Streptococcus salivarius K12 | GRN 591 (in PDF 1.92 MB) |
|
590 | Pyrroloquinoline quinone | At the notifier's request, FDA ceased to evaluate this notice | |
589 | Xylanase from Aspergillus niger | FDA has no questions | |
588 | Zeaxanthin from Capsicum annum (paprika) | FDA has no questions; some uses may require a color additive listing | |
587 | Acetolate decaroxylase from Bacillus brevis produced in Bacillus licheniformis | FDA has no questions | |
586 | Taurine | FDA has no questions | |
585 | 1-methylcyclopropene | FDA has no questions | |
584 | Cellulase from Penicillium funiculosum | FDA has no questions | |
583 | Esterified propoxylated glycerol | FDA has no questions | |
468 | Preparation containing the bacterial monophages, Fo1a and S16, specific to Salmonella | Supplemental Response Letter (in PDF 98.08 KB) |
|
452 | Enzyme-modified steviol glycosides | Additional Correspondence (in PDF 282 KB) |
|
435 | Preparation consisting of six bacterial monophage specific to Salmonella enterica (monophage cocktail) | Supplemental letter (in PDF 74 KB) Supplemental Response Letter 2 (in PDF 235 KB) |
|
399 | Preparation of Bacillus coagulans strain GBI-30, 6086 spores | GRN 399 with Amendment (in PDF 1.2 MB) |
|
379 | Tuna oil | GRN 379 with Amendment (in PDF 6.5 MB) |
|
229 | Methylsulfonylmethane | Additional correspondence (in PDF 45 KB) |
|
183 | Phospholipase A2 enzyme preparation from Aspergillus niger expressing a gene encoding a porcine phospholipase A2 | Additional correspondence (in PDF 46 KB) |